BXRX
$0.72
Baudax Bio
($.03)
(3.39%)
BXRX
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.72)
Revenue:  N/A
Thursday
Nov 10
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BXRX reports earnings?
Beat
Meet
Miss

Where is BXRX's stock price going from here?
Up
Flat
Down
Stock chart of BXRX
Analysts
Summary of analysts' recommendations for BXRX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Baudax Bio Inc. is based in Malvern, Pennsylvania.